Gene therapy to terminate tachyarrhythmias

Area of Science:

• Cardiovascular Medicine
• Molecular Biology
• Genetics

Background:

• Current treatments for tachyarrhythmias, including drug therapy, catheter ablation, and implantable devices, have limitations in efficacy and curability.
• Certain fatal tachyarrhythmias remain refractory to existing treatments, highlighting the need for novel therapeutic strategies.
• Gene therapy has emerged as a potential groundbreaking treatment for arrhythmias, with accumulating basic and translational research.

Purpose of the Study:

• To review the current status of gene therapy for treating cardiac arrhythmias.
• To discuss susceptible arrhythmias, cardiac administration routes, and vector types for gene therapy.
• To explore advancements in gene delivery and genome editing technologies for arrhythmia treatment.

Main Methods:

• Literature review of gene therapy approaches for tachyarrhythmias.
• Analysis of current gene delivery technologies and genome editing techniques.
• Discussion of challenges and future directions for clinical translation.

Main Results:

• Gene therapy shows significant promise as a future treatment modality for various arrhythmias.
• Key considerations for gene therapy include the choice of susceptible arrhythmias, cardiac administration routes, and vector selection.
• Progress in gene delivery and genome editing technologies is advancing the potential of gene therapy.

Conclusions:

• Gene therapy represents a highly promising frontier for managing arrhythmias, particularly those resistant to conventional therapies.
• Achieving safe, localized, homogeneous, and durable gene transfer is essential for successful clinical implementation.
• Continued technological innovation in gene delivery and editing is critical to realizing the full therapeutic potential of gene therapy for arrhythmias.